Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by A minibody to the fifth component of complement

Transplantation

Volumn 86, Issue 10, 2008, Pages 1445-1451

  Ferraresso, Mariano ^a,b,f   MacOr, Paolo ^c,d   Valente, Marialuisa ^e   Barbera, Mila Della ^e   D'Amelio, Fabio ^a   Borghi, Orietta ^a   Raschi, Elena ^a   Durigutto, Paolo ^c   Meroni, Pierluigi ^a   Tedesco, Francesco ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d ADIENNE Pharma and Biotech   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Complement activation; Ischemia reperfusion injury; Organ transplantation.

Indexed keywords

COMPLEMENT COMPONENT C5 NEUTRALIZING MINIANTIBODY; COMPLEMENT COMPONENT C5A; CREATINE KINASE; IMMUNOGLOBULIN G1; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIBODY; COMPLEMENT COMPONENT C5;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; ABDOMINAL AORTA; ANIMAL; DRUG EFFECT; HEART CONTRACTION; HETEROTOPIC TRANSPLANTATION; IMMUNOLOGY; INFERIOR CAVA VEIN; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; NECROSIS; NICK END LABELING; PATHOLOGY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; SPRAGUE DAWLEY RAT; SUPERIOR CAVA VEIN; THORACIC AORTA;

ANIMALS; ANTIBODIES; AORTA, ABDOMINAL; AORTA, THORACIC; COMPLEMENT ACTIVATION; COMPLEMENT C5; HEART TRANSPLANTATION; IN SITU NICK-END LABELING; INJECTIONS, INTRAVENOUS; MALE; MYOCARDIAL CONTRACTION; NECROSIS; POSTOPERATIVE COMPLICATIONS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; TRANSPLANTATION, HETEROTOPIC; VENA CAVA, INFERIOR; VENA CAVA, SUPERIOR;

EID: 58149345075     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818a68e2     Document Type: Article

References (37)

1. Koning OH, Ploeg RJ, van Bockel JH,etal. Risk factors for delayed graft function in cadaveric kidney transplantation: A prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. Transplantation 1997; 63: 1620.
2. Shoskes DA, Shahed AR, Kim S. Delayed graft function. Influence on outcome and strategies for prevention. Urol Clin North Am 2001; 28: 721.
3. Perico N, Cattaneo D, Sayegh MH, et al. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814.
4. Halloran PF, Hunsicker LG. Delayed graft function: State of the art, November 10-11, 2000 Summit meeting, Scottsdale, Arizona, USA. Am J Transplant 2001; 1: 115.
5. Halloran PF, Aprile MA, Farewell V, et al. Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine. Transplantation 1988; 46: 223.
6. Herrero-Fresneda I, Torras J, Cruzado JM, et al. Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy? Am J Pathol 2003; 162: 127.
7. Azuma H, Nadeau K, Takada M, et al. Cellular and molecular predictors of chronic renal dysfunction after initial ischemia/reperfusion injury of a single kidney. Transplantation 1997; 64: 190.
8. Salmela K, Wramner L, Ekberg H, et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: A report of the European Anti-ICAM-1 Renal Transplant Study Group. Transplantation 1999; 67: 729.
9. Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994; 45: 1731.
10. Mister M, Noris M, Szymczuk J, et al. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int 2002; 61: 1064.
11. Sacks SH, Chowdhury P, Zhou W. Role of the complement system in rejection. Curr Opin Immunol 2003; 15: 487.
12. Arumugam TV, Magnus T, Woodruff TM, et al. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta 2006; 374: 33.
13. Chowdhury P, Zhou W, Sacks SH. Complement in renal transplantation. Nephron Clin Pract 2003; 95: c3.
14. Casarsa C, De Luigi A, Pausa M, et al. Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain. Eur J Immunol 2003; 33: 1260.
15. Bossi F, Fischetti F, Pellis V, et al. Platelet-activating factor and kinindependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 2004; 173: 6921.
16. Dobrina A, Pausa M, Fischetti F, et al. Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. Blood 2002; 99: 185.
17. Fischetti F, Tedesco F. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity 2006; 39: 417.
18. Hattori R, Hamilton KK, McEver RP, et al. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264: 9053.
19. Kilgore KS, Shen JP, Miller BF, et al. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995; 155: 1434.
20. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994; 94: 1147.
21. Tedesco F,Pausa M, Nardon E, et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997; 185: 1619.
22. Patel H, Smith RA, Sacks SH, et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 2006; 17: 1102.
23. Pratt JR, Jones ME, Dong J, et al. Nontransgenic hyperexpression of a complement regulatorindonor kidney modulates transplant ischemia/ reperfusion damage, acute rejection, and chronic nephropathy. Am J Pathol 2003; 163: 1457.
24. Baldwin WM III, Samaniego-Picota M, Kasper EK, et al. Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation 1999; 68: 894.
25. Vakeva AP, Agah A, Rollins SA, et al. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97: 2259.
26. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg 1969; 57: 225.
27. FischettiF,DuriguttoP,PellisV,et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340.
28. Marzari R, Sblattero D, Macor P, et al. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: In vitro and in vivo studies. Eur J Immunol 2002; 32: 2773.
29. Al-Rufaie HK, Florio RA, Olsen EG. Comparison of the haematoxylin basic fuchsin picric acid method and the fluorescence of haematoxylin and eosin stained sections for the identification of early myocardial infarction. J Clin Pathol 1983; 36: 646.
30. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493.
31. Tanaka M, Mokhtari GK, Terry RD, et al. Prolonged cold ischemia in rat cardiac allografts promotes ischemia-reperfusion injury and the development of graft coronary artery disease in a linear fashion.J Heart Lung Transplant 2005; 24: 1906.
32. Sakaguchi T, Sawa Y, Fukushima N, et al. A novel strategy of decoy transfection against nuclear factor-kappaB in myocardial preservation. Ann Thorac Surg 2001; 71: 624.
33. Huang J, Nakamura K, Ito Y, et al. Bcl-xL gene transfer inhibits Bax translocation and prolongs cardiac cold preservation time in rats. Circulation 2005; 112: 76.
34. Fischetti F, Durigutto P, Macor P, et al. Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. Arthritis Rheum 2007; 56: 1187.
35. Kajstura J,Cheng W,ReissK, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variablesofinfarct sizeinrats. Lab Invest 1996; 74: 86.
36. Scarabelli T, Stephanou A, Rayment N, et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation 2001; 104: 253.
37. Ohno M, Takemura G, Ohno A, et al. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with In situ nick end-labeling. Circulation 1998; 98: 1422.